Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

Icli F., AKBULUT H., Utkan G., Yalcin B., Dincol D., Isikdogan A., ...Daha Fazla

JOURNAL OF SURGICAL ONCOLOGY, cilt.95, sa.6, ss.507-512, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 95 Sayı: 6
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1002/jso.20728
  • Dergi Adı: JOURNAL OF SURGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.507-512
  • Anahtar Kelimeler: advanced pancreatic carcinoma, low molecular weight heparin, cisplatin, gemcitabine, nadroparine, RECURRENT VENOUS THROMBOEMBOLISM, CELL LUNG-CANCER, RANDOMIZED-TRIAL, IN-VITRO, CARCINOMA, WARFARIN, SURVIVAL, PHASE, ANTICOAGULATION, CHEMOTHERAPY
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: In this non-randomized study we aimed to assess the efficacy of the addition of low molecular weight heparin (LMWH) to gemcitabine (GEM) plus cisplatinum (CDDP) combination chemotherapy on survival by prevention of thromboembolic complications in patients with advanced pancreatic cancer (APC).